A Johns Hopkins analysis published in JACC: Advances used AI to study GLP-1 discussions on Reddit and found recurring themes of cost struggles, insurance battles, side effects, and questions about how to take the medications, exactly the friction points that push people toward DIY workarounds
These medications slow gastric emptying and increase feelings of fullness, leading to reduced calorie intake and weight loss
A July 2024 Harvard study found diabetes patients prescribed semaglutide were over four times likely to develop NAION, while those prescribed it for weight loss were over seven times likely to develop this condition
On the other hand, INSL-5 targets a GPCR known as GPR142, also known as RXFP4, a receptor found to be expressed by the NCI-H716 cell line (54), and both and -cells in the pancreas, and its activation directly stimulates the expression of GLP-1 and insulin, representing a possible new pharmacological tool for the treatment of type 2 diabetes (77, 221), and supporting a possible role for INSL-5 in the incretin effect